Oklahoma board of nursing crna inclusionary formulary
CRNA Inclusionary Formulary To be granted authority to select, order, obtain and administer drugs, Certified Registered Nurse Anesthetists (CRNAs) must hold a current Registered Nurse license, be recognized as a CRNA in Oklahoma and meet the continuing education requirements noted in the Rules of the Oklahoma Board of Nursing, specifically 485:10-18-2. Pursuant to 59 O.S. § 567.3a.10 [Oklahoma Nursing Practice Act], a Formulary Advisory Council has been established to develop and submit to the Board recommendations for an inclusionary formulary. The following Board-approved CRNA Inclusionary Formulary lists drugs that may be ordered, selected, obtained or administered during the perioperative and periobstetrical periods by CRNAs who have been granted authority by the Board to select, order, obtain, and administer drugs. 4:00 Antihistamine Drugs
First Generation Antihistamines Diphenhydramine Hydrochloride Promethazine Hydrochloride (see also 28:24.92 and 28:16.08.24) [CAUTION:BE AWARE OF PEDIATRIC RESTRICTIONS. CAUTION WITH IV USE.] 12:00 Autonomic Agents
Parasympathomimetic (Cholinergic) Agents
Atropine Glycopyrrolate Ipratropium Bromide Scopolomine
12:12.08.04 Non-selective β-Adrenergic Agonists
12:12.08.08 Selective β1-Adrenergic Agonists
12:12.08.12 Selective β2-Adrenergic Agonists
Board Reviewed w/o Revision: 1/28/99; 5/23/06
Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11; 5/22/12; 5/28/13 P: /Administration/Executive/Policies/Practice/CRNAIncForm
Sympatholytic (Adrenergic Blocking) Agents
12:16.04.04 Non-selective α-Adrenergic Blocking Agents
Skeletal Muscle Relaxants (all intravenous future new drugs approved)
12:20.08 Direct-acting Skeletal Muscle Relaxants
Blood Derivatives
Blood and Blood Components (not in AHFS) 20:00 Blood Formation and Coagulation
Antihemorrhagic Agents 20:28.08 Antiheparin Agents
24:00 Cardiovascular Drugs
Board Reviewed w/o Revision: 1/28/99; 5/23/06
Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11; 5/22/12; 5/28/13 P: /Administration/Executive/Policies/Practice/CRNAIncForm
24:28.92 Calcium-Channel Blocking Agents, Miscellaneous
Renin-Angiotensin-Aldosterone System Inhibitors
24:32.04 Angiotensin-Converting Enzyme Inhibitors
Central Nervous System Agents 28:04
General Anesthetics (all in this class approved including future new drugs)
28:04.92 General Anesthetics, Miscellaneous
28:08.04 Nonsteroidal Antiflammatory Agents
28:08.04.08 Cyclooxygenase-2 (COX-2) Inhibitors
28:08.04.92 Other Nonsteroidal Anti-inflammatory Agents
28:08.08 Opiate Agonists (all in this class approved including future new drugs)
[NOTE: BE AWARE OF PEDIATRIC CAUTION]***
Hydrocodone Hydromorphone Levorphanol* Meperidine Morphine Remifentanil* Sufentanil Citrate Tramadol
28:08.12 Opiate Partial Agonists (all in this class approved including future new drugs)
28:08.92 Analgesics and Antipyretic, Miscellaneous
Board Reviewed w/o Revision: 1/28/99; 5/23/06
Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11; 5/22/12; 5/28/13 P: /Administration/Executive/Policies/Practice/CRNAIncForm
Opiate Antagonists (all in this class approved including future new drugs) Nalmefene* Naloxone Naltrexone
Ethotoin FosphenytoinPhenytoin
28:12.92 Anticonvulsants, Miscellaneous
Anorexigenic Agents and Respiratory and CNS Stimulants
Anxiolytics, Sedatives, and Hypnotics 28:24.04 Barbiturates* (all in this class approved including future new drugs)
28:24.08 Benzodiazepines (all in this class approved including future new drugs)
Diazepam Lorazepam Midazolam Temazepam*
28:24.92 Anxiolytics, Sedatives and Hypnotics; Miscellaneous
[NOTE: Adult dosage not to exceed a total dose of 1.25 mg; Pediatric dosage not to exceed a one-time dose of 10 mcg/kg.]
Central Nervous System Agents, Miscellaneous
Board Reviewed w/o Revision: 1/28/99; 5/23/06
Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11; 5/22/12; 5/28/13 P: /Administration/Executive/Policies/Practice/CRNAIncForm
Diagnostic Agents Electrolytic, Caloric, and Water Balance 40:08
Dextran 70 Dextran75 (not in AHFS) [CAUTION: POTENTIAL COMPLICATION OF ANAPHYLACTIC REACTION TO DEXTRAN 75]
Electrolyte Solutions* Hetastarch [CAUTION: POTENTIAL COMPLICATION OF ANAPHYLACTIC REACTION TO HETASTARCH IN PATIENTS ALLERGIC TO LATEX.]
Salt and Sugar Substitutes (not in AHFS)
Irrigating Solutions* Sterile water for injection*
Respiratory Tract Agents (all in this class approved including future new drugs) 48:08
Benzonatate* Codeine Dextromethorphan Hydrocodone
Mucolytic Agents Acetylcysteine (see also 92:12)
Eye, Ear, Nose, and Throat (EENT) Preparations 52:16
Board Reviewed w/o Revision: 1/28/99; 5/23/06
Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11; 5/22/12; 5/28/13 P: /Administration/Executive/Policies/Practice/CRNAIncForm
Gastrointestinal Drugs 56:04
Aluminum Carbonate Aluminum Hydroxide Aluminum Phosphate Antacids Calcium Carbonate Charcoal, Activated Dihydroxyaluminum Aminoacetate Dihydroxyaluminum Sodium Carbonate Magaldrate Magnesium Carbonate Magnesium Hydroxide Magnesium Oxide Magnesium Trisilicate Sodium Bicarbonate
Hormones and Synthetic Substitutes 68:04
Adrenals (all in this class approved including future new drugs) Beclomethasone
Board Reviewed w/o Revision: 1/28/99; 5/23/06
Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11; 5/22/12; 5/28/13 P: /Administration/Executive/Policies/Practice/CRNAIncForm
Betamethasone Cortisone Acetate Dexamethasone Fludrocortisone Flunisolide* Hydrocortisone Methlyprednisolone Prednisolone Prednisone Triamcinolone
Local Anesthetics (all in this class approved including future new drugs) Articaine Bupivacaine Chloroprocaine Lidocaine Mepivacaine Prilocaine Procaine (not in AHFS) Ropivacaine (not in AHFS) Tetracaine Oxytocics Carboprost Tromethamine* Dinoprostone Ergonovine/Methergonovine Oxytocin Sodium Chloride 20% Injection Urea 40-50% Injection Skin and Mucous Membrane Agents 84:08
Antipruritics and Local Anesthetics (all in this class approved including future new drugs) Benzocaine* Dibucaine* Doxepin* Ethyl Chloride* Phenazopyridine*
Board Reviewed w/o Revision: 1/28/99; 5/23/06
Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11; 5/22/12; 5/28/13 P: /Administration/Executive/Policies/Practice/CRNAIncForm
Smooth Muscle Relaxants 86:16
Respiratory Smooth Muscle Relaxants Aminophylline Theophyllines
Vitamins* Miscellaneous Therapeutic Agents 92:12 Antidotes
[NOTE: ACLS Algorithm medications are listed according to the classification system in the AHFS Drug Information resource.]
Regulatory Authority: 59 O.S. §567.4b. C. Reference: American Hospital Formulary Service®. AHFS Drug Information (2013). Published by Authority of the Board of the American Society of Health-System Pharmacists®, Bethesda, MD. *Omitted from the print version of AHFS Drug Information because of space limitations, as stated by the publisher. May view the AHFS Drug Information website: **Reference for Ketamine: *** Reference for Codeine precautions
Board Reviewed w/o Revision: 1/28/99; 5/23/06
Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11; 5/22/12; 5/28/13 P: /Administration/Executive/Policies/Practice/CRNAIncForm
AGGIORNAMENTI TERAPIA FARMACOLOGICA DELL’ASMA BRONCHIALE CRONICO Premessa 3. Obiettivi del trattamento dell’asma a lungo In questi ultimi anni si sono registrati indiscutibi-li progressi nel trattamento dell’asma bronchiale eI principali obiettivi del trattamento dell’asmaciò grazie ad una ampia e continua diffusione, e con-seguente attuazione, di corrette linee di interve
Statin use in postmenopausal women increases risk of type 2 diabetes, but benefits may still outweigh risks A recent study has found that that the use of statins in postmenopausal women is associated with an increased risk of diabetes mel itus (DM). However, further studies are warranted, and some experts say that the benefits stil outweigh the risks. The study set out to evaluate whether